Dyadic Reports Q2 2025 Financial Results, Highlights Leadership Transformation and Milestones in Life Sciences and Nutrition Markets.

Dyadic International, a biotechnology company, reported Q2 2025 financial results and highlighted recent progress. The company completed a strategic leadership and operational transformation, rebranded as Dyadic Applied BioSolutions, and redesigned its corporate website. Dyadic achieved key development and commercial milestones in life sciences and nutrition markets, advanced multiple recombinant protein programs, and raised $5.3 million in equity. The company's cash position stands at $7.3 million as of June 30, 2025, with an additional $5.3 million from the equity offering in August 2025. Dyadic plans to host an earnings call at 5:00 pm ET.